Table 2 Univariate association between individual parameters and survival
From: Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
Clinical and demographic markers | Genetic markers | Protein markers | ||||||
---|---|---|---|---|---|---|---|---|
P -value per subcellular localisation | ||||||||
Parameters | P -value | Parameters | P -value | Parameters | Membranous | Cytoplasmic | Granular | Nuclear |
Age | 0.49 | |||||||
R0 vs R1/R2 | 0.057 | EGFR FISH | EGFR | 0.63 | 0.10 (0.099a) | — | 0 | |
Adenocarcinoma vs all other | 0.54 | No gain vs other | 0.15 | HER2 | 1 | 0.33 | — | — |
BAC vs all other | 0.43 | High polysomy vs other | 0.13 | pAKT.473 | — | 0.22 | — | 0.62 |
Squamous cell vs all other | 0.42 | Amplification vs other | 0.72 | pAKT.309 | 0.53 | 1 | — | 0.95 |
Large cell carcinoma vs all other | 0.9 | PTEN | — | 0.63 | — | 0.69 | ||
Smoking (non vs current vs Former) | 0.79 | EGFR mutation | pERK | — | 0.36 | 0.011 | 0.39 | |
Stage (I vs II vs III) | 0.04 | WT vs other | 0.15 | pSTAT3 | 0.97 | 0.50 | — | 0.056 (0.11b) |
Stage (I vs II/III) | 0.015 (0.03c) | SNP vs other | 0.70 | pSTAT5 | 0.76 | 0.31 | — | 0.33 |
Pre-operative CT vs not | 0.45 | Mutant vs other | 0.33 | E-cadherin | 0.32 | 0.031 | — | — |
Post-operative CT vs not | 0.5 | Vimentin | 0.29 | 0.80 | — | 0.45 | ||
Post-operative RT vs not | 0.15 | KRAS mutation | HIF-1α | — | — | — | 0.55 | |
Pre-operative chemo-radiation vs not | 0.031d | WT vs other | 0.08 | pCMET.1003 | 0.8 | 0.11 | — | — |
Other diseases vs not | 0.37 | SNP vs other | 0.84 | pCMET.1349 | — | 0.49 | — | 0.69 |
Mutant vs other | 0.08 | pCMET.1230 | 0.88 | 0.90 | — | 0.68 | ||
pCMET.1365 | 0.55 | 0.87 | — | 0.86 |